125I-labeled OP-1 is locally retained in a rabbit lumbar fusion model

Clinical Orthopaedics and Related Research

Volumn 466, Issue 1, 2008, Pages 210-215

  Erickson, Benjamin P ^a   Pierce, Allen R ^b   Simpson, Andrew K ^a   Nash, John ^c   Grauer, Jonathan N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stryker Orthopaedics   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; OSTEOGENIC PROTEIN 1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; AUTORADIOGRAPHY; BONE GRAFT; DRUG DISTRIBUTION; DRUG EXCRETION; LIQUID SCINTILLATION COUNTING; PRIORITY JOURNAL; RABBIT; SPINE FUSION; ANIMAL; ANIMAL MODEL; BONE DEVELOPMENT; BONE REGENERATION; DRUG EFFECT; IMPLANT; LUMBAR VERTEBRA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SCINTILLATION COUNTING;

ANIMALS; AUTORADIOGRAPHY; BONE MORPHOGENETIC PROTEINS; IMPLANTS, EXPERIMENTAL; IODINE RADIOISOTOPES; LUMBAR VERTEBRAE; MODELS, ANIMAL; OSSEOINTEGRATION; OSTEOGENESIS; RABBITS; SCINTILLATION COUNTING; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 41149105810     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-007-0017-2     Document Type: Article

References (22)

1. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996;329:300-309.
2. Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertransverse process spinal fusion model: radiographic, histologic, and biomechanical healing characteristics. Spine. 1995;20:412-420.
3. Bomback DA, Grauer JN, Lugo R, Troiano N, Patel TCh, Friedlaender GE. Comparison of posterolateral lumbar fusion rates of Grafton putty and OP-1 putty in an athymic rat model. Spine. 2004;29:1612-1617.
4. Callis TE, Cao D, Wang DZ. Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes. Circ Res. 2005;97:992-1000.
5. Erulkar JS, Grauer JN, Patel TC, Panjabi MM. Flexibility analysis of posterolateral fusions in a New Zealand white rabbit model. Spine. 2001;26:1125-1130.
6. Feiertag MA, Boden SD, Schimandle JH, Norman JT. A rabbit model for nonunion of lumbar intertransverse process spine arthrodesis. Spine. 1996;21:27-31.
7. Grauer JN, Beiner JM, Kwon BK, Vaccaro AR. Bone graft alternatives for spinal fusion. BioDrugs. 2003;17:391-394.
8. Grauer JN, Patel TC, Erulkar JS, Troiano NW, Panjabi MM, Friedlaender GE. Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion. Spine. 2001;26:127-133.
9. Israelsson C, Lewén A, Kylberg A, Usoskin D, Althini S, Lindeberg J, Deng CX, Fukuda T, Wang Y, Kaartinen V, Mishina Y, Hillered L, Ebendal T. Genetically modified bone morphogenetic protein signaling alters traumatic brain injury-induced gene expression responses in the adult mouse. J Neurosci Res. 2006;84:47-57.
10. Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine. 2006;31:1067-1074.
11. Liao SS, Guan K, Cui FZ, Shi SS, Sun TS. Lumbar spinal fusion with a mineralized collagen matrix and rhBMP-2 in a rabbit model. Spine. 2003;28:1954-1960.
12. 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res. 2002;20:1050-1059.
13. Morone MA, Boden SD. Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine. 1998;23:159-167.
14. Patel TC, Erulkar JS, Grauer JN, Troiano NW, Panjabi MM, Friedlaender GE. Osteogenic protein-1 overcomes the inhibitory effect of nicotine on posterolateral lumbar fusion. Spine. 2001;26:1656-1661.
15. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci. 1982;71:474-475.
16. Uludag H, D'Augusta D, Golden J, Li J, Timony G, Riedel R, Wozney JM. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res. 2000;50:227-238.
17. Uludag H, Friess W, Williams D, Porter T, Timony G, D'Augusta D, Blake C, Palmer R, Biron B, Wozney J. rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics. Ann NY Acad Sci. 1999;875:369-378.
18. Uludag H, Gao T, Porter TJ, Friess W, Wozney JM. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am. 2001;83(suppl 1):S128-S135.
19. Urist MR, DeLange RJ, Finerman GAM. Bone cell differentiation and growth factors: induced activity of chondro-osteogenetic DNA. Science. 1983;220:680-686.
20. Vaccaro AR, Anderson DG, Patel T, Fischgrund J, Truumees E, Herkowitz HN, Phillips F, Hilibrand A, Albert TJ, Wetzel T, McCulloch JA. Comparison of OP-1 putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine. 2005;30:2709-2716.
21. Wetzel P, Haag J, Campean V, Goldschmeding R, Atalla A, Amann K, Aigner T. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int. 2006;70:717-723.
22. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res. 1999;367(suppl):S95-S106.